Published in:
Open Access
01-12-2018 | Editorial
Methotrexate: who would have predicted its importance in rheumatoid arthritis?
Author:
Michael E. Weinblatt
Published in:
Arthritis Research & Therapy
|
Issue 1/2018
Login to get access
Excerpt
Forty years ago, the US Food and Drug Administration approved low dose methotrexate (MTX) for the treatment of active rheumatoid arthritis (RA). MTX was previously approved for a variety of malignancies at high doses and at low doses for psoriasis. Little did one anticipate in 1988 that MTX would change the course of RA. I had the pleasure of being directly involved in the development of MTX in RA and it has been extremely gratifying to see the impact of MTX in RA. …